Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $2.09B
• Dividend Yield: N/A
• Average Volume (3M): 2.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.37
• Revenue Growth: -82.38%
• EPS Growth: -164.76%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -1.24
• Shares Outstanding: 100,557,090
• 10 Day Avg. Volume: 2,685,991
• 30 Day Avg. Volume: 2,187,011
• PEG Ratio: 6.75
• Price to Book (P/B): 1.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.42
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 33.96
• Enterprise Value/Ebitda: -1.44
• 1Y Price Target: $45.00
• Price Target Upside: 108.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 56 Neutral
• Price Target: $22.50 ▲(4.46%Upside)

Beam Therapeutics is facing significant financial challenges typical of its industry, reflected in negative earnings and cash flow metrics. However, a recent strategic acquisition and strong technical indicators provide positive momentum. The stock's valuation is hampered by negative earnings, but the acquisition could offer long-term growth opportunities.

Positive Factors

Clinical Trials

The BEACON trial update reinforces clinical differentiation of BEAM-101 in sickle cell disease, with patients achieving a favorable hemoglobin profile and no vaso-occlusive crises reported post-treatment.

Regulatory Progress

Beam anticipates that data from 30 to 45 patients from the BEACON trial may be sufficient to support a biologics license application for BEAM-101, viewing it as a potentially best-in-class option for patients with severe sickle cell disease.

Safety and Efficacy

Beam's data continue to demonstrate best-in-class efficacy and safety as compared to peers.

Negative Factors

Market Challenges

This program remains several years from approval in a market that has proven to be a heavy commercial lift for much larger companies.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Beam Therapeutics generates revenue through strategic collaborations, licensing agreements, and development milestones with other pharmaceutical companies. The company leverages its proprietary base editing platform to enter into partnerships where it grants rights to use its technology for developing specific therapies. Beam may receive upfront payments, milestone payments based on the achievement of certain development stages, and potential royalties on sales of any successfully commercialized products. Additionally, Beam invests in its internal pipeline of therapeutic candidates, which, upon successful clinical development and regulatory approval, could yield revenue from product sales. Significant partnerships with established pharmaceutical firms also contribute to its financial growth, providing both financial support and technological validation.

Beam Therapeutics Financial Statement Overview

Summary

Beam Therapeutics is facing financial challenges typical of early-stage biotechnology firms, with significant net income losses and operational cash burn. The balance sheet shows moderate leverage, but negative free cash flow highlights increasing cash consumption without revenue growth.

Income Statement

Beam Therapeutics shows significant challenges in profitability, with consistent negative net income and EBIT over recent periods. The gross profit margin is relatively healthy, indicating some cost control, but the net profit margin remains deeply negative due to high operating expenses. Revenue growth is stagnant, especially compared to the larger increases in operating losses, indicating a struggle to scale operations profitably.

Balance Sheet

The company's balance sheet reflects moderate leverage with a debt-to-equity ratio that suggests manageable debt levels relative to equity. However, the return on equity is negative due to consistent net losses, indicating that shareholders' equity is not generating positive returns. The equity ratio indicates a stable capital structure, with a significant portion of assets funded by equity, which is a positive aspect amidst financial struggles.

Cash Flow

Beam Therapeutics has negative free cash flow, reflecting ongoing operational cash burn. The operating cash flow to net income ratio indicates that cash flow is less negative than net income, suggesting non-cash expenses. However, the negative free cash flow growth rate is concerning, indicating increasing cash consumption without corresponding revenue growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	41.59M	-59.67M	38.34M	35.40M	-103.16M
EBITDA	-383.98M	-156.47M	-324.33M	-392.46M	-128.03M
Net Income	-376.74M	-132.53M	-263.59M	-341.36M	-256.42M
Balance Sheet
Total Assets	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	161.43M	172.69M	179.00M	142.35M	100.23M
Total Liabilities	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Positive. The current price of 21.54 is above the 20-day moving average (MA) of 19.55, above the 50-day MA of 18.16, and below the 200-day MA of 22.84, indicating a neutral trend. The MACD of 0.91 indicates Negative momentum. The RSI at 63.86 is Neutral, neither overbought nor oversold. The STOCH value of 52.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	60 Neutral	$1.25B	―	-57.92%	―	-13.37%	2.57%
BEAM	56 Neutral	$2.09B	―	-38.04%	―	-82.38%	-164.76%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
PHAT	48 Neutral	$555.02M	―	181.41%	―	3055.71%	-18.80%
IMVT	45 Neutral	$3.06B	―	-62.46%	―	―	-43.10%
ETNB	42 Neutral	$1.53B	―	-69.30%	―	―	-68.13%

Beam Therapeutics Corporate Events

Beam Therapeutics Acquires Early-Stage Life Sciences Firm

On July 1, 2025, Beam Therapeutics Inc. acquired an early-stage life sciences company, agreeing to issue 403,128 shares of its common stock as an upfront payment and up to $89 million in additional milestone payments. This strategic acquisition is expected to enhance Beam’s capabilities and market position, potentially impacting its operations and stakeholders positively.

The most recent analyst rating on (BEAM) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics Confirms Key Decisions at Annual Meeting

On June 4, 2025, Beam Therapeutics held its annual meeting of stockholders, where key decisions were made regarding the company’s leadership and operations. The election of Class II directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation were all confirmed, reflecting strong shareholder support and potentially impacting the company’s governance and financial oversight.

The most recent analyst rating on (BEAM) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.